PMID- 29373924
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1615-7109 (Electronic)
IS  - 1203-4754 (Linking)
VI  - 22
IP  - 3
DP  - 2018 May/Jun
TI  - Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: 
      Retrospective Study.
PG  - 290-296
LID - 10.1177/1203475418755982 [doi]
AB  - BACKGROUND: Apremilast is a new oral drug for the treatment of moderate to severe 
      plaque psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its 
      efficacy and safety data are limited; hence, real-world outcomes are important 
      for elucidating the full spectrum of its adverse events (AEs) and expanding 
      generalizability of clinical trial findings. OBJECTIVE: Assess the efficacy and 
      safety of apremilast monotherapy in real-world practice. METHODS: A retrospective 
      chart review was conducted in 2 academic dermatology practices. Efficacy was 
      measured as the proportion of patients achieving a >/=75% reduction from baseline 
      Psoriasis Area and Severity Index score (PASI-75) or a Psoriasis Global 
      Assessment (PGA) score of 0 (clear) or 1 (almost clear) at 16 weeks. Safety was 
      measured as the proportion of patients reporting >/=1 AE at 16 weeks. RESULTS: 
      Thirty-four patients were included. EFFICACY: 19 patients (55.9%) achieved 
      PASI-75 or PGA 0/1. SAFETY: 23 patients (67.6%) experienced >/=1 AEs. Five patients 
      (14.7%) withdrew treatment prior to week 16 due to AEs. One patient withdrew 
      treatment due to mood lability and depression. Common AEs included headache 
      (32.4%), nausea (20.6%), diarrhoea (14.7%), weight loss (8.8%), and loose stool 
      (8.8%). CONCLUSION: Apremilast monotherapy had higher efficacy with similar 
      safety outcomes in the real world compared to clinical trials. There were higher 
      proportions of reported headaches compared to clinical trials. This study 
      supports the apremilast monotherapy clinical trial findings, suggesting that it 
      has an acceptable safety profile and significantly reduces the severity of 
      moderate to severe plaque psoriasis. Limitations include the retrospective nature 
      of the study.
FAU - Ighani, Arvin
AU  - Ighani A
AUID- ORCID: 0000-0002-2164-3609
AD  - 1 Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Georgakopoulos, Jorge R
AU  - Georgakopoulos JR
AD  - 2 Schulich School of Medicine and Dentistry, Western University, London, ON, 
      Canada.
FAU - Zhou, Linda L
AU  - Zhou LL
AD  - 3 Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
FAU - Walsh, Scott
AU  - Walsh S
AD  - 4 Division of Dermatology, Department of Medicine, University of Toronto, 
      Toronto, ON, Canada.
FAU - Shear, Neil
AU  - Shear N
AUID- ORCID: 0000-0001-9151-1145
AD  - 4 Division of Dermatology, Department of Medicine, University of Toronto, 
      Toronto, ON, Canada.
FAU - Yeung, Jensen
AU  - Yeung J
AD  - 4 Division of Dermatology, Department of Medicine, University of Toronto, 
      Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20180126
PL  - United States
TA  - J Cutan Med Surg
JT  - Journal of cutaneous medicine and surgery
JID - 9614685
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - UP7QBP99PN (apremilast)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy/pathology
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Thalidomide/adverse effects/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - apremilast
OT  - clinical practice
OT  - monotherapy
OT  - phosphodiesterase inhibitor
OT  - plaque psoriasis
EDAT- 2018/01/28 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/01/28 06:00
PHST- 2018/01/28 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/01/28 06:00 [entrez]
AID - 10.1177/1203475418755982 [doi]
PST - ppublish
SO  - J Cutan Med Surg. 2018 May/Jun;22(3):290-296. doi: 10.1177/1203475418755982. Epub 
      2018 Jan 26.